These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20027374)

  • 1. The dual nature of extracellular ATP as a concentration-dependent platelet P2X1 agonist and antagonist.
    Karunarathne W; Ku CJ; Spence DM
    Integr Biol (Camb); 2009 Dec; 1(11-12):655-63. PubMed ID: 20027374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red blood cell stimulation of platelet nitric oxide production indicated by quantitative monitoring of the communication between cells in the bloodstream.
    Carroll JS; Ku CJ; Karunarathne W; Spence DM
    Anal Chem; 2007 Jul; 79(14):5133-8. PubMed ID: 17580956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
    Packham MA; Mustard JF
    Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of U46619 induced human platelet aggregation by aspirin.
    Kim JM; Koo YK; Jin J; Lee YY; Park S; Yun-Choi HS
    Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: Evidence for the reduced platelet activities in Parkinson's disease.
    Lim KM; Kim HH; Bae ON; Noh JY; Kim KY; Kim SH; Chung SM; Shin S; Kim HY; Chung JH
    Platelets; 2009 May; 20(3):163-70. PubMed ID: 19437333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of streptozocin-induced diabetes on platelet aggregation as determined by impedance aggregometry and platelet secretion: a possible role for nitric oxide.
    Judge S; Mammen E; Dunbar JC
    J Assoc Acad Minor Phys; 1995; 6(3):100-4. PubMed ID: 7663098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
    Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S
    Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.
    Fagura MS; Dainty IA; McKay GD; Kirk IP; Humphries RG; Robertson MJ; Dougall IG; Leff P
    Br J Pharmacol; 1998 May; 124(1):157-64. PubMed ID: 9630355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of purine nucleotides on purinergic P2 platelet receptors by small angle light scattering].
    Sakaev MR; Mindukshev IV; Lesiovskaia EE; Petrishchev NN; Krivchenko AI
    Eksp Klin Farmakol; 2000; 63(3):65-9. PubMed ID: 10934601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation.
    Cauwenberghs S; Feijge MA; Hageman G; Hoylaerts M; Akkerman JW; Curvers J; Heemskerk JW
    Transfusion; 2006 Jun; 46(6):1018-28. PubMed ID: 16734820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence determination of nitric oxide production in stimulated and activated platelets.
    Ku CJ; Karunarathne W; Kenyon S; Root P; Spence D
    Anal Chem; 2007 Mar; 79(6):2421-6. PubMed ID: 17288406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide.
    Klinge JM; Topf HG; Trusen B; Rauh M; Rascher W; Dötsch J
    Crit Care Med; 2003 Jul; 31(7):2010-4. PubMed ID: 12847397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No requirement of P2X1 purinoceptors for platelet aggregation.
    Takano S; Kimura J; Matsuoka I; Ono T
    Eur J Pharmacol; 1999 May; 372(3):305-9. PubMed ID: 10395026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cangrelor attenuates coated-platelet formation.
    Norgard NB; Hann CL; Dale GL
    Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between platelet density and platelet aggregation, ATP release, and cytosolic-free calcium mobilization in rabbits.
    Li BY; Li WH; Bai Y
    Zhongguo Yao Li Xue Bao; 1995 Jul; 16(4):367-72. PubMed ID: 7668113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
    Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
    Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of platelet function by polymorphonuclear leukocytes.
    Zatta A; Prosdocimi M; Bertelé V; Bazzoni G; Del Maschio A
    J Lab Clin Med; 1990 Nov; 116(5):651-60. PubMed ID: 2146349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADP receptors of platelets and their inhibition.
    Gachet C
    Thromb Haemost; 2001 Jul; 86(1):222-32. PubMed ID: 11487010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.